COPENHAGEN, Denmark, May 27, 2015 (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Company will present at the Jefferies 2015 Global Healthcare Conference in New York, NY and the Goldman Sachs 36th Annual Global Healthcare Conference in Palos Verdes, CA.
Jens Bager, President and CEO, will provide an overview of the Company and its key programmes on Wednesday, 3 June at 1.30 PM (Eastern time).
Flemming Pedersen, CFO and Executive Vice President, will provide an overview of the Company and its key programmes on Wednesday, 10 June at 8.40 AM Pacific Time (11.40 AM Eastern time).
For further information please contact:
Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Janet Dally, tel. +1 609-466-0466, mobile 732-319-2833
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy - a treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck, Torii, Abbott and bioCSL to commercialise sublingual allergy immunotherapy tablets in North America, Japan, Russia, Australia and New Zealand, respectively. The company is headquartered in Hoersholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net.